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Abstract
Eph receptor tyrosine kinase signaling regulates cancer initiation
and metastatic progression through multiple mechanisms. Studies
of tumor-cell-autonomous effects of Eph receptors demonstrate
their dual roles in tumor suppression and tumor promotion. In
addition, Eph molecules function in the tumor microenvironment,
such as in vascular endothelial cells, influencing the ability of these
molecules to promote carcinoma progression and metastasis. The
complex nature of Eph receptor signaling and crosstalk with other
receptor tyrosine kinases presents a unique challenge and an
opportunity to develop therapeutic intervention strategies for
targeting breast cancer.
Introduction
The Eph receptors comprise the largest family of receptor
tyrosine kinases. The family is subdivided into class A and
class B, based on sequence homology and binding affinity for
two distinct types of membrane-anchored ephrin ligands.
Ephrins and Eph receptors are key regulators of physiological
and pathological processes in development and disease (for
reviews, see [1-6]). Expression of many of the Eph receptors
is often elevated in a wide variety of tumors, including breast
cancer, yet their precise roles in cancer are not well
understood. Data from recent studies demonstrated that Eph
receptors and ephrins function in both tumor cells and the
tumor microenvironment, with dual roles in tumor suppression
and tumor promotion. In this review we highlight key results in
the area of Eph receptor expression, tumor biology, and
therapeutics in breast cancer, with an emphasis on EphA2
and EphB4 receptors.
Eph receptor in mammary gland development
Mammary epithelial morphogenesis is a complex develop-
mental process during which an extensive network of
branched ducts forms from a rudimentary epithelial bud. This
process, termed ‘branching morphogenesis’, is regulated by
endocrine hormones and local paracrine interaction between
the developing epithelial ducts and their adjacent mesen-
chymal stroma. Expression of multiple Eph family receptors
and their ligands has been reported in the mammary gland.
Ephrin-B2 is expressed on the luminal cells, and its receptor,
EphB4, is expressed complementarily on myoepithelial cells
in mice. The expression of EphB4 and ephrin-B2 is depen-
dent on estrogen and is regulated during the estrus cycle [7].
Over-expression of EphB4 under the control of the mouse
mammary tumor virus (MMTV) promoter/enhancer induced
delayed development of the mammary epithelium at puberty
and during pregnancy, with unscheduled epithelial apoptotic
cell death during pregnancy and abnormal epithelial DNA
synthesis at early postlactational involution, indicating an
abnormal response to proliferative/apoptotic signals [8].
In addition to EphB4, developmentally controlled expression
of EphA2 in the mammary epithelium has also been reported
[9,10]. Loss of EphA2 receptor resulted in decreased
penetration of mammary epithelium into fat pad, reduced
epithelial proliferation, and inhibition of epithelial branching,
suggesting a positive role for EphA2 during normal mammary
gland development (Vaught and coworkers, unpublished
data). EphA2 is also expressed in human mammary epithelial
cells [11-14]. Fournier and coworkers analyzed gene
expression in two nonmalignant human mammary epithelial
cell lines in three-dimensional cultures. When these cells
underwent growth arrest and differentiated into polarized
acini, EphA2 levels were significantly decreased [15],
consistent with the observation that EphA2 is expressed at a
low level in normal mammary gland epithelium, whereas
expression increases in breast cancer [3]. Indeed, analysis of
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a set of 19 genes that were downregulated in differentiated
acini of human mammary epithelial cells in three-dimensional
cultures against two independent breast cancer microarray
datasets revealed that increased EphA2 levels are associated
with poor patient prognosis [13,15]. Taken together, these
data suggest that EphA2 is required for mammary gland
morphogenesis, and increased EphA2 expression in human
breast cancer is associated with tumor cell malignancy and
poor patient survival.
Role of Eph receptors in breast cancer
promotion
In screens for new receptor tyrosine kinases in cancer, many
Eph receptors were found to be over-expressed in multiple
types of human tumors [1,3]. Of Eph receptors expressed in
breast cancer [11,12,16,17], EphA2 and EphB4 are the two
that have been most extensively studied. EphA2 is expressed
at low levels in normal human breast epithelium [9,18] and
over-expressed in 60% to 80% of breast cancers [11,12,19]
(Brantley-Sieders and Chen, unpublished data). Experimen-
tally induced over-expression of EphA2 resulted in malignant
transformation of nontransformed MCF10A breast cells and
enhanced malignancy of pancreatic carcinoma cells [12,20].
Conversely, small interfering RNA (siRNA)-mediated inhibition
of EphA2 expression impaired malignant progression of
pancreatic, ovarian, and mesothelioma tumor cell lines, and
over-expression of dominant-negative EphA2 constructs
suppressed growth and metastasis of 4T1 metastatic mouse
mammary adenocarcinoma cells in vivo [20-23]. To deter-
mine whether EphA2 plays a causative role in breast cancer
initiation and metastatic progression, EphA2 knockout mice
were crossed to MMTV-Neu transgenic animals that express
a rat homolog of the ErbB2 receptor tyrosine kinase. Loss of
EphA2 impairs both tumor initiation and lung metastasis in
MMTV-Neu mice [24]. Similarly, EphB4 levels are also
elevated in human breast cancer [17]. EphB4 knockdown
inhibited breast cancer survival, migration, and invasion in
vitro and tumor growth in a xenograft model in vivo [25].
Furthermore, over-expression of EphB4 in the mammary
epithelium accelerates tumor onset and lung metastasis in
MMTV-Neu animals [8]. Taken together, these data indicate a
role for Eph receptor in tumor promotion.
The mechanisms regulating the oncogenic effects of Eph
receptors are not entirely clear. In many instances, Eph
receptors in tumor cells are under-phosphorylated in spite of
over-expression. This could be due to increased activity of
phosphotyrosine phosphatase or loss of E-cadherin in tumor
cells. E-cadherin regulates cell surface localization of EphA2
and/or loss of cell-cell contacts prevent interaction with
endogenous ephrin ligands [26-28]. Because both Eph
receptors and ligands are membrane anchored and reside in
separate microdomains on the cell surface [29,30], loss of
cell-cell adhesion in tumor cells impairs activation of Eph
receptor by ephrins on adjacent cells. Thus, the oncogenic
activity of Eph receptors appears to be ligand independent.
High levels of EphA2 receptor have been shown to interact
physically with both the epidermal growth factor receptor
(EGFR) and ErbB2, promoting Erk and RhoA GTPase activity
[24,31]. These data suggest that crosstalk between Eph
receptor and other oncogenic pathways promotes tumor cell
malignancy, possibly in an ephrin-independent manner.
Furthermore, a high level of EphA2 was found to upregulate
matrix metalloproteinase 2 [20,32] and extracellular matrix
protein fibronectin [33]. Modulation of tumor cell interaction
with the microenvironment may also contribute to Eph
receptor function in tumor promotion.
Role of Eph receptors in tumor suppression
Many studies have demonstrated a role for Eph receptor in
tumor suppression. Stimulation of EphA receptors with
soluble ephrin-A1-Fc ligand reduced Erk phosphorylation in
tumor cell lines, fibroblasts, and primary aortic endothelial
cells, and suppressed growth of primary keratinocytes and
prostate carcinoma cells [34,35]. Macrae and coworkers [35]
also reported that treatment of human breast cancer cell lines
with ephrin-A1-Fc attenuated epidermal growth factor
mediated phosphorylation of Erk and inhibited transformation
of NIH3T3 cells expressing v-erbB2. In addition, EphA2-
deficient gene-trap mice displayed increased susceptibility to
chemical carcinogen-induced skin cancer, accompanied by
increased tumor cell proliferation and phosphorylation of Erk
[36]. These data suggest that ephrin-A-induced EphA2
receptor forward signaling inhibits tumor malignancy.
In addition to EphA2, EphB4 forward signaling also appears
to inhibit tumor progression. Systemic delivery of ephrin-B2-
Fc inhibits the growth of MDA-MB-435 tumor xenografts
[37]. EphB4 forward signaling apparently activates the
Abl/Crk pathway to inhibit tumor cell growth and motility in
breast cancer cells [37]. Furthermore, EphB receptor signal-
ing is also able to suppress tumor expansion in colon cancer.
Over-expression of a dominant negative EphB2 cytoplasmic
truncation mutant or knockout of EphB3 or ephrin-B1 in the
intestinal epithelium significantly increases tumor numbers
and tumor invasiveness in the APCmin/+ model [38,39]. EphB
receptors have been proposed to compartmentalize the
expansion of colon cancer cells through a mechanism
dependent on E-cadherin-mediated adhesion [39].
In summary, ephrin-induced Eph receptor forward signaling in
nontransformed mammary epithelial cells appears to
transduce an inhibitory signal that may keep cells quiescent
and noninvasive [34,35,37]. Upon tumor initiation, Eph
receptor expression is upregulated by oncogenic signaling
pathways such as the Ras/mitogen-activated protein kinase
pathway in breast cancer or the Wnt-β-catenin pathway in
colon cancer, whereas their ephrin ligands are often down-
regulated [35,40] or unable to bind to receptor because of
loss of cell-cell adhesion [28]. Crosstalk between elevated
Eph receptors and other oncogenes, such as the ErbB family
of receptor tyrosine kinases [24,31], leads to enhanced cellPage 3 of 8
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proliferation and tumorigenesis, presumably independently of
ephrin stimulation (Figure 1).
Eph receptors and ephrins in tumor
angiogenesis
Tumor angiogenesis is critical for growth, survival, and
malignant progression of tumors. Tumor vessels not only
supply the nutrients and oxygen necessary for tumor cell
growth and survival, but they also actively promote malignant
progression by providing an entry point into the circulation for
the dissemination of metastatic cells [41]. In addition to
regulating developmental angiogenesis, Eph receptors and
ephrins have also emerged as critical regulators of tumor
angiogenesis. The first ligand discovered for the Eph
receptors, ephrin-A1, is a tumor necrosis factor-α inducible
gene in endothelial cells [42]. Early studies demonstrated
that ephrin-A1 promotes angiogenic responses in vitro and
corneal neovascularization in vivo [42]. Ephrin-A1 is
expressed in developing embryonic and tumor vasculature
[11,18,43]. More importantly, ephrin-A1 is further induced by
hypoxia in tumors that are resistant to anti-vascular
endothelial growth factor (VEGF) therapy [44]. Ephrin-A1
knockout mice were recently generated. Interestingly, ephrin-
A1-deficient mice survive to adulthood with only minor heart
valve defects (Frieden and Chen, unpublished data),
suggesting that loss of ephrin-A1 can be functionally
compensated for in vascular development. It remains to be
determined whether tumor angiogenesis is affected in these
mice.
EphA2, a major receptor for ephrin-A1 in vascular endothelial
cells, plays a significant role in promoting tumor angio-
genesis. Implantation of tumor cells into the mammary gland
of EphA2-deficient host mice results in reduced tumor
volume, microvascular density, and lung metastasis. These
findings suggest that loss of EphA2 in the tumor micro-
environment impairs tumor angiogenesis and metastatic
progression [24,45]. Indeed, EphA2-deficient vascular endo-
thelial cells fail to migrate and assemble in response to angio-
genic cues in vitro [46] and are unable to incorporate into
tumor blood vessels when they are co-transplanted with
tumor cells in vivo [45,47], indicating a critical function for
EphA2 in tumor angiogenesis.
In contrast to the complex effects of Eph signaling in tumor
cells, Eph receptor signaling in vascular endothelial cells
promotes tumor angiogenesis. Brantley-Sieders and co-
workers [46] showed that EphA2 receptor forward signaling
regulates endothelial cell migration and assembly through
phosphoinositide-3 kinase (PI3K)-mediated Rac1 GTPase
activation. A yeast two-hybrid screen for EphA2 interacting
proteins revealed that Vav2 and Vav3 guanine nucleotide
Available online http://breast-cancer-research.com/content/10/6/217
Figure 1
Working model for Eph receptor function in tumor promotion and tumor suppression. In normal cells, engagement of Eph receptors with ephrins on
adjacent cells in trans induces receptor forward signaling, leading to inhibition of Ras/mitogen-activated protein kinase (MAPK) activity, or
suppression of Crk activation via Abl kinase activity, and tumor suppression. In tumor cells, disruption of cell-cell junctions inhibits Eph receptor
interaction with endogenous ephrins in trans. In addition, Eph receptors are often upregulated whereas ephrins are downregulated. Crosstalk
between Eph receptors and other receptor tyrosine kinases such as ErbB2 and epidermal growth factor receptor (EGFR) results in increased
activity of the Ras-MAPK pathway and the RhoA GTPase, and enhanced tumor malignancy.exchange factors are recruited to activated EphA2 receptor
and subsequently elevate Rac1-GTP levels [48]. Loss of
Vav2 and Vav3 inhibits Rac1 activity and ephrin-A1-induced
angiogenic responses both in vitro and in vivo [48]. Further-
more, Fang and coworkers [47] mapped phosphorylated
tyrosine residues of EphA2 in vascular endothelial cells.
Ephrin-A1-induced phosphorylation of Y587 and Y593 in the
EphA2 receptor recruits Vav2 and Vav3 exchange factors,
whereas phosphorylation of Y734 provides a docking site for
the p85 regulatory subunit of PI3K. EphA2-null endothelial
cells reconstituted with EphA2 mutants lacking these binding
sites fail to activate Rac1 GTPase, are defective in cell
migration and assembly in vitro, and are unable to incorporate
into tumor vasculature in vivo. These findings suggest a
critical role for these tyrosine phosphorylation sites in
transducing EphA2 forward signaling in vascular endothelial
cells and validated the involvement of PI3K-dependent
activation of Vav exchange factors and Rac1 GTPase in
ephrin-A1-induced angiogenesis.
Gene targeting studies have established ephrin-B2 and
EphB4 as key regulators of embryonic vascular development
[49,50]. Ephrin-B2 expression has also been observed in
tumor vasculature in a variety of tumor types, suggesting that
this ligand may regulate tumor neovascularization [51-53]. In
support of this hypothesis, A375 melanomas form smaller,
less vascularized tumors in the presence of the soluble,
monomeric EphB4 extracellular domain in vivo [54]. Soluble
EphB4 may act, at least in part, by preventing binding of
tumor cell EphB receptors to ephrin-B2-positive endothelium,
thus disrupting tumor angiogenesis. Further support for this
hypothesis is provided by studies in which over-expression of
a truncated cytoplasmic deletion EphB4 receptor construct
produced increased tumor growth and vascularity in
mammary tumors, probably through ephrin-B2 mediated
reverse signaling in host endothelium [53]. Upregulation of
ephrin-B1 expression has been reported in hepatocellular
carcinoma, and over-expression of ephrin-B1 enhances tumor
neovascularization  in vivo [55]. Although proliferation of
ephrin-B1 over-expressing cells was not affected in culture,
soluble ephrin-B1-Fc enhanced endothelial cell proliferation
and migration in vitro, suggesting that at least one function of
ephrin-B1 in tumor progression involves facilitation of tumor
angiogenesis [55,56]. Taken together, these studies reveal a
critical role for B class receptors and ligands in tumor
progression and vascular recruitment for multiple types of
human cancer.
Eph receptors as targets for breast cancer
therapeutics
Because Eph receptors are often over-expressed in
malignant cancer, and reduction in Eph receptor levels was
found to be efficacious in tumor inhibition in animal models, a
wide range of therapeutic strategies targeting Eph receptors
has been recently developed for cancer treatment. These
approaches include activating monoclonal antibodies against
Eph receptors, ligand- or activating antibody-cytotoxin conju-
gates, siRNA, antagonistic peptides, small molecular inhibi-
tors, and immunotherapy (Table 1).
Carles-Kinch and coworkers [57] first reported that activating
monoclonal antibodies against EphA2 inhibited tumor growth
in soft agar and prevented tubular network formation on
Matrigel. Coffman and colleagues [58] subsequently showed
that similar anti-EphA2 agonistic antibodies selectively bind
epitopes on malignant cells and decrease tumor growth in
xenograft tumor models. The mechanism of action of these
antibodies appears to mimic ephrin ligands, inducing
receptor phosphorylation and subsequent internalization and
degradation [57,58]. However, it is not clear whether
agonistic antibody-induced EphA2 receptor forward signaling
also conveys an inhibitory signal to promote tumor suppres-
sion. Regardless, the ability of ephrins and anti-EphA2 anti-
bodies to distinguish malignant from nonmalignant cells
prompted the development of ligand- or agonistic antibody-
toxin conjugates. Wykosky and coworkers [59] reported a
novel cytotoxin composed of the ephrin-A1 ligand conjugated
to a genetically modified bacterial toxin, namely Pseudo-
monas exotoxin A. Ephrin-A1-conjugates exhibit potent and
dose-dependent killing of cancer cells that express high
levels of the EphA2 receptor, including glioblastoma multi-
forme cells, as well as breast and prostate cancer cells. An
anti-EphA2 antibody conjugated with the microtubule poly-
merization inhibitor monomethylauristatin phenylalanine (MMAF)
has also been developed by MedImmune Inc. (Gaithersburg,
MD, USA). The conjugated antibody significantly inhibits tumor
cell growth both in vitro and in vivo without any observable
adverse effects [60]. These findings make ephrinA1- or anti-
EphA2-based cytotoxins a potentially attractive therapeutic
strategy in the treatment of breast cancer.
siRNAs that specifically inhibit gene expression have rapidly
become a powerful tool in both mechanistic studies and
targeted therapeutics. It was previously reported that siRNAs
directed against EphA2 resulted in decreased protein
expression and decreased tumor growth in a pancreatic
cancer xenograft model [20]. More recently, siRNAs against
EphA2 were incorporated into packaging liposomes
composed of the neutral lipid 1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine (DOPC) for efficient in vivo delivery.
Neutral liposome-coupled EphA2 siRNA reduced tumor
growth in an orthotopic mouse model of ovarian cancer both
in the presence and absence of paclitaxel [21,61], suggest-
ing the feasibility of siRNA as a clinically applicable thera-
peutic approach.
Eph receptors and ephrins have emerged as critical
regulators of tumor angiogenesis, making them attractive
targets for inhibition of neovascularization [1,5]. More impor-
tantly, Eph/ephrin signaling provides a possible mechanism
responsible for resistance to anti-VEGF therapy [44]. Soluble
Eph receptors have been used to inhibit endogenous Eph
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genesis in vivo [18,54,62,63]. More recently, the Pasquale
laboratory has developed a peptide, TNYL-RAW, which
competes with ephrin-B2 for binding to EphB4 receptor
[64,65]. In addition, two isomeric small molecule compounds
have been identified that selectively inhibit ephrin binding to
EphA4 and EphA2 [66]. Both the EphB4 blocking peptide
and EphA2/EphA4 antagonistic compounds inhibit Eph
receptor phosphorylation and capillary-like tube formation in
human umbilical vein endothelial cells [66,67]. This suggests
that they can potentially serve as starting points from which to
develop antiangiogenic therapies in cancer treatment.
In addition to being direct targets for therapeutic intervention,
EphA2-derived peptides have been used in a dendritic cell-
based vaccine for immunotherapy in glioblastoma multiforme
and colon cancer [68-70]. Early studies showed that, in renal
cell carcinoma, EphA2-derived peptides induced specific,
tumor-reactive CD8+ and CD4+ T-cell responses. The
reactivity of CD8+ T cells to EphA2 peptides was stronger in
T cells isolated from postsurgery disease-free patients than in
those from patients with active disease, suggesting that the
immune system of cancer patients actively monitors EphA2-
derived epitopes [70]. More recently, vaccination using
dendritic cells pulsed with EphA2 peptides in a murine colon
cancer model revealed that immunization inhibited the growth
of MC38 tumors expressing EphA2, but did not have an
effect on BL6 tumors that do not express EphA2 [68].
Furthermore, Hatano and coworkers [69] reported that stimu-
lation of  peripheral blood mononuclear cells from glioma
patients and control healthy donors with dendritic cells loaded
with EphA2 peptide elicited an antigen-specific cytotoxic T
cell response. These preliminary results demonstrate that
EphA2-derived epitopes may represent important candidate
vaccines to be tested in clinical trials for the treatment of
malignant cancers.
Conclusions
Eph receptor expression is often increased in human cancer,
including breast cancer. The available evidence suggests that
ligand-induced Eph receptor signaling in tumor cells plays a
role in tumor suppression, whereas ligand-independent Eph
receptor signaling functions in tumor promotion. Further
investigation into molecular pathways that may be
differentially regulated by EphA2 activation in response to
endogenous ephrin ligands versus activation by association
with other receptor tyrosine kinases, such as ErbB2, could
provide insight into the differential effects of EphA2 signaling
in breast cancer. Moreover, analysis of EphA2 and ErbB2/
EGFR co-expression in human breast cancer samples,
coupled with genetic evidence suggesting that EphA2 co-
operates with ErbB2 to promote tumor progression in mice
[24], may provide a rationale for combining EphA2-targeted
therapies with inhibitors of ErbB2/EGFR signaling in patients
that express both receptors.
For EphB4, expression patterns and function of B class Eph
receptors in intestinal epithelial patterning and tumorigenesis
Available online http://breast-cancer-research.com/content/10/6/217
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Table 1
Therapeutic strategies targeting Eph receptors
Treatment Target Tumor Institution References
Activating antibodies EphA2 Breast cancer MedImmune/AstraZeneca [24,57,58]
Antibody-conjugates EphA2 Prostate cancer, glioma MedImmune/AstraZeneca [60]
Ephrin-conjugates EphA2 Glioblastoma Wake Forest University [59]
siRNAs EphA2 Ovarian cancer MD Anderson [21]
Pancreatic cancer Harvard [20]
Soluble receptors EphA Breast cancer Immunex/Amgen [18,62,63] 
Pancreatic cancer Cephalon
EphB Melanoma University of Frieburg [54]
Inhibitory peptides EphB4 Angiogenesis Burnham Institute [64,67,73]
EphB2 [65]
EphA2 [74]
Small molecule inhibitors EphA2 Angiogenesis Burnham Institute [66]
EphA4
Immunotherapy EphA2 Colon cancer Osaka University [68]
Glioblastoma University of Pittsburgh [69]provide a model for elucidating the roles played by this and
other EphB receptors in breast cancer. Expression and func-
tional studies suggest that EphB/ephrin-B family members
coordinate positional patterning of specific cell types in
intestinal epithelium to prevent intermingling, and expression
of several B class molecules are regulated by the Wnt/β-
catenin signaling pathway in the gut [40,71]. Complementary
expression of Ephrin-B2 on luminal cells and EphB4 on
myoepithelial cells in the mouse mammary gland [7] could
function to maintain a boundary between these cell types,
similar to what is observed in the intestinal models.
Moreover, because several members of the Wnt signaling
pathway have been implicated in mammary gland
development and breast cancer (for review see [72]), similar
upregulation of EphB receptors by Wnt/β-catenin could
contribute to breast cancer progression. Further research is
required to test these hypotheses.
In addition to a tumor cell autonomous role, Eph receptor also
regulates important tumor-host interactions, notably in
stimulation of tumor angiogenesis during tumor progression.
As such, targeting Eph receptors holds both promises and
challenges for therapeutic intervention in breast cancer. The
effects of Eph receptors on both tumor cells and tumor
microenvironment provide a unique therapeutic opportunity to
block multiple steps in tumor progression. At the same time,
the nature of bidirectional signaling of the Eph/ephrin system,
and contribution of cell-type and context-dependent factors
to the multi-faceted role of Eph receptors in cancer cells may
complicate the development of effective therapeutic agents.
Further research in dissecting bidirectional signaling and the
context-dependent role of Eph receptors in cancer is
essential for developing successful therapeutic strategies.
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